|
Volumn 16, Issue 5, 1999, Pages 854-855
|
Therapeutic perspective in cancerology for angiogenesis inhibitors;Perspectives therapeutiques des inhibiteurs de l'angiogenese en cancerologie
a
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANGIOGENESIS INHIBITOR;
ANGIOSTATIN;
ENDOSTATIN;
FIBROBLAST GROWTH FACTOR;
MARIMASTAT;
TISSUE INHIBITOR OF METALLOPROTEINASE 1;
TRANSFORMING GROWTH FACTOR BETA1;
VASCULOTROPIN;
ANTINEOPLASTIC AGENT;
COLLAGEN;
HYDROXAMIC ACID;
MATRIX METALLOPROTEINASE;
PEPTIDE FRAGMENT;
PLASMINOGEN;
PROTEINASE INHIBITOR;
ANTINEOPLASTIC ACTIVITY;
CANCER;
CANCER THERAPY;
CLINICAL TRIAL;
DRUG MECHANISM;
HUMAN;
LUNG CANCER;
NONHUMAN;
REVIEW;
TUMOR VASCULARIZATION;
ANIMAL;
ARTICLE;
CONTROLLED CLINICAL TRIAL;
DRUG ANTAGONISM;
EXPERIMENTAL NEOPLASM;
LUNG TUMOR;
MOUSE;
NEOPLASM;
NEOVASCULARIZATION (PATHOLOGY);
RANDOMIZED CONTROLLED TRIAL;
SMALL CELL CARCINOMA;
ANGIOGENESIS INHIBITORS;
ANGIOSTATINS;
ANIMALS;
ANTINEOPLASTIC AGENTS;
CARCINOMA, SMALL CELL;
COLLAGEN;
ENDOSTATINS;
HUMANS;
HYDROXAMIC ACIDS;
LUNG NEOPLASMS;
MATRIX METALLOPROTEINASES;
MICE;
NEOPLASMS;
NEOPLASMS, EXPERIMENTAL;
NEOVASCULARIZATION, PATHOLOGIC;
PEPTIDE FRAGMENTS;
PLASMINOGEN;
PROTEASE INHIBITORS;
RANDOMIZED CONTROLLED TRIALS;
|
EID: 0033217310
PISSN: 07618425
EISSN: None
Source Type: Journal
DOI: None Document Type: Review |
Times cited : (2)
|
References (6)
|